Literature DB >> 11060065

Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma.

D G Murphy1, L Côté, M Fauvel, P René, J Vincelette.   

Abstract

The performance and characteristics of Roche COBAS AMPLICOR HIV-1 MONITOR version 1.5 (CA MONITOR 1.5) UltraSensitive (usCA MONITOR 1. 5) and Standard (stCA MONITOR 1.5) procedures, Organon Teknika NucliSens HIV-1 RNA QT with Extractor (NucliSens), and Bayer Quantiplex HIV RNA version 3.0 (bDNA 3.0) were compared in a multicenter trial. Samples used in this study included 460 plasma specimens from human immunodeficiency virus (HIV) type 1 (HIV-1)-infected persons, 100 plasma specimens from HIV antibody (anti-HIV)-negative persons, and culture supernatants of HIV-1 subtype A to E isolates diluted in anti-HIV-negative plasma. Overall, bDNA 3.0 showed the least variation in RNA measures upon repeat testing. For the Roche assays, usCA MONITOR 1.5 displayed less variation in RNA measures than stCA MONITOR 1.5. NucliSens, at an input volume of 2 ml, showed the best sensitivity. Deming regression analysis indicated that the results of all three assays were significantly correlated (P < 0.0001). However, the mean difference in values between CA MONITOR 1.5 and bDNA 3.0 (0.274 log(10) RNA copies/ml; 95% confidence interval, 0.192 to 0.356) was significantly different from 0, indicating that CA MONITOR 1.5 values were regularly higher than bDNA 3.0 values. Upon testing of 100 anti-HIV-negative plasma specimens, usCA MONITOR 1.5 and NucliSens displayed 100% specificity, while bDNA 3.0 showed 98% specificity. NucliSens quantified 2 of 10 non-subtype B viral isolates at 1 log(10) lower than both CA MONITOR 1.5 and bDNA 3.0. For NucliSens, testing of specimens with greater than 1,000 RNA copies/ml at input volumes of 0.1, 0.2, and 2.0 ml did not affect the quality of results. Additional factors differing between assays included specimen throughput and volume requirements, limit of detection, ease of execution, instrument work space, and costs of disposal. These characteristics, along with assay performance, should be considered when one is selecting a viral load assay.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11060065      PMCID： PMC87538     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  37 in total

1.  False-positive HIV diagnosis by HIV-1 plasma viral load testing.

Authors:  D H Havlichek; E Hage-Korban
Journal:  Ann Intern Med       Date:  1999-11-16       Impact factor: 25.391

2.  Comparative evaluation of two branched-DNA human immunodeficiency virus type 1 RNA quantification assays with lower detection limits of 50 and 500 copies per milliliter.

Authors:  C Manegold; C Krempe; H Jablonowski; L Kajala; M Dietrich; O Adams
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.

Authors:  D V Havlir; N S Hellmann; C J Petropoulos; J M Whitcomb; A C Collier; M S Hirsch; P Tebas; J P Sommadossi; D D Richman
Journal:  JAMA       Date:  2000-01-12       Impact factor: 56.272

4.  Rapid and simple method for purification of nucleic acids.

Authors:  R Boom; C J Sol; M M Salimans; C L Jansen; P M Wertheim-van Dillen; J van der Noordaa
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

Review 5.  Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.

Authors:  C C Carpenter; D A Cooper; M A Fischl; J M Gatell; B G Gazzard; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; M Schechter; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  2000-01-19       Impact factor: 56.272

6.  Relationship of incremental specimen volumes and enhanced detection of human immunodeficiency virus type 1 RNA with nucleic acid amplification technology.

Authors:  D J Witt; M Kemper; A Stead; C C Ginocchio; A M Caliendo
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

7.  Human immunodeficiency virus (HIV) subtype surveillance of African-born persons at risk for group O and group N HIV infections in the United States.

Authors:  P S Sullivan; A N Do; D Ellenberger; C P Pau; S Paul; K Robbins; M Kalish; C Storck; C A Schable; H Wise; C Tetteh; J L Jones; J McFarland; C Yang; R B Lal; J W Ward
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

8.  Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5.

Authors:  T Elbeik; E Charlebois; P Nassos; J Kahn; F M Hecht; D Yajko; V Ng; K Hadley
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

9.  The use of viral culture and p24 antigen testing to diagnose human immunodeficiency virus infection in neonates. The HIV Infection in Newborns French Collaborative Study Group.

Authors:  M Burgard; M J Mayaux; S Blanche; A Ferroni; M L Guihard-Moscato; M C Allemon; N Ciraru-Vigneron; G Firtion; C Floch; F Guillot
Journal:  N Engl J Med       Date:  1992-10-22       Impact factor: 91.245

10.  Strategies for long-term success in the treatment of HIV infection.

Authors:  J E Gallant
Journal:  JAMA       Date:  2000-03-08       Impact factor: 56.272
View more
  26 in total

1.  Principles of quantitation of viral loads using nucleic acid sequence-based amplification in combination with homogeneous detection using molecular beacons.

Authors:  Jos J A M Weusten; Wim M Carpay; Tom A M Oosterlaken; Martien C A van Zuijlen; Paul A van de Wiel
Journal:  Nucleic Acids Res       Date:  2002-03-15       Impact factor: 16.971

Review 2.  Characteristics and applications of nucleic acid sequence-based amplification (NASBA).

Authors:  Birgit Deiman; Pierre van Aarle; Peter Sillekens
Journal:  Mol Biotechnol       Date:  2002-02       Impact factor: 2.695

3.  Stochastic processes defining sensitivity and variability of internally calibrated quantitative NASBA-based viral load assays.

Authors:  Jos J A M Weusten; Pieter A W M Wouters; Martien C A van Zuijlen; Paul A van de Wiel
Journal:  Nucleic Acids Res       Date:  2002-12-15       Impact factor: 16.971

4.  Performance of NucliSens HIV-1 EasyQ Version 2.0 compared with six commercially available quantitative nucleic acid assays for detection of HIV-1 in China.

Authors:  Sihong Xu; Aijing Song; Jianhui Nie; Xiuhua Li; Youchun Wang
Journal:  Mol Diagn Ther       Date:  2010-10-01       Impact factor: 4.074

5.  Evaluation of a real-time nucleic acid sequence-based amplification assay using molecular beacons for detection of human immunodeficiency virus type 1.

Authors:  D R McClernon; C Vavro; M St Clair
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

6.  Intra- and interlaboratory variabilities of results obtained with the Quantiplex human immunodeficiency virus type 1 RNA bDNA assay, version 3.0.

Authors:  J A Kellogg; P V Atria; J C Sanders; M E Eyster
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

7.  Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT.

Authors:  Priscilla Swanson; Carmen de Mendoza; Yagnya Joshi; Alan Golden; Richard L Hodinka; Vincent Soriano; Sushil G Devare; John Hackett
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

8.  Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms.

Authors:  Rute Antunes; Sofia Figueiredo; Inês Bártolo; Manuel Pinheiro; Lino Rosado; Isabel Soares; Helena Lourenço; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

9.  Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts.

Authors:  Erica E M Moodie; Nitika Pant Pai; Marina B Klein
Journal:  PLoS One       Date:  2009-02-18       Impact factor: 3.240

10.  Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands.

Authors:  Luuk Gras; Suzanne Jurriaans; Margreet Bakker; Ard van Sighem; Daniela Bezemer; Christophe Fraser; Joep Lange; Jan M Prins; Ben Berkhout; Frank de Wolf
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.